| Chronic Kidney Diseases

Ozempic vs Jardiance

Side-by-side clinical, coverage, and cost comparison for chronic kidney diseases.

Deep comparison between: Ozempic vs Jardiance with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsJardiance has a higher rate of injection site reactions vs Ozempic based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Jardiance but not Ozempic, including UnitedHealthcare

Category

Ozempic

Jardiance

At A Glance

RouteSC injection

FrequencyOnce weekly

ClassGLP-1 receptor agonist

RouteOral

FrequencyOnce daily

ClassSGLT2 inhibitor

Indications

Diabetes Mellitus, Non-Insulin-Dependent
Chronic Kidney Diseases

Heart failure
Chronic Kidney Diseases
Diabetes Mellitus, Non-Insulin-Dependent

Dosing

Diabetes Mellitus, Non-Insulin-Dependent Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; escalate to 1 mg then 2 mg based on glycemic control (max 2 mg once weekly).

Chronic Kidney Diseases Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; maintenance dose is 1 mg once weekly.

Heart failure, Chronic Kidney Diseases 10 mg orally once daily in the morning, taken with or without food.

Diabetes Mellitus, Non-Insulin-Dependent 10 mg orally once daily in the morning, taken with or without food; may increase to 25 mg once daily in patients tolerating 10 mg for additional glycemic control.

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
Serious hypersensitivity reaction to semaglutide or any excipient in Ozempic

Hypersensitivity to empagliflozin or any excipient in JARDIANCE (reactions such as angioedema have occurred)

Drug Interactions

944View drug interactions

416View drug interactions

Adverse Reactions

Most common (>=5%) Nausea, vomiting, diarrhea, abdominal pain, constipation

Serious Risk of thyroid C-cell tumors, acute pancreatitis, diabetic retinopathy complications, hypoglycemia with insulin secretagogues or insulin, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration

Postmarketing Ileus, intestinal obstruction, severe constipation, fecal impaction, anaphylaxis, angioedema, rash, urticaria, cholecystitis, cholecystectomy, dysesthesia, headache, pulmonary aspiration, acute kidney injury, alopecia

Most common (>=2%) Urinary tract infection, female genital mycotic infections, upper respiratory tract infection, increased urination, dyslipidemia, arthralgia, male genital mycotic infections, nausea

Serious Diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), hypoglycemia (with insulin or sulfonylurea), hypersensitivity reactions

Postmarketing Constipation, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, skin reactions (rash, urticaria)

Pharmacology

Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, stimulating insulin secretion and lowering glucagon secretion in a glucose-dependent manner, with a minor delay in gastric emptying; prolonged half-life is achieved through albumin binding, which reduces renal clearance and protects against metabolic degradation.

Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion; it also reduces sodium reabsorption, which may increase tubuloglomerular feedback, reduce intraglomerular pressure, and lower cardiac pre- and afterload.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Ozempic